Evolus (NASDAQ:EOLS) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS) in a research note released on Tuesday,Benzinga reports. They currently have a $22.00 price target on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a research note on Thursday, November 7th.

Evolus Stock Down 0.8 %

Shares of Evolus stock opened at $14.02 on Tuesday. The company has a 50-day simple moving average of $11.75 and a two-hundred day simple moving average of $13.75. The stock has a market capitalization of $887.75 million, a PE ratio of -15.41 and a beta of 1.32. Evolus has a 52-week low of $9.25 and a 52-week high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Hedge Funds Weigh In On Evolus

Several hedge funds and other institutional investors have recently modified their holdings of the company. KBC Group NV purchased a new stake in Evolus during the fourth quarter valued at $49,000. Quarry LP purchased a new stake in shares of Evolus during the 2nd quarter valued at about $54,000. Point72 Asset Management L.P. bought a new position in shares of Evolus in the 3rd quarter worth approximately $132,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Evolus in the third quarter worth approximately $191,000. Finally, Profund Advisors LLC bought a new stake in Evolus during the second quarter valued at approximately $130,000. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.